LDS/Medical Tests/Apolipoprotein E (Apo E) Genotyping

Apolipoprotein E (Apo E) Genotyping

Apolipoprotein E (apoE) is a ligand for the LDL and apoE receptor, involved in clearance of apoB-containing lipoproteins, specifically chylomicrons such as VLDL, and VLDL remnants. In addition, it participates in HDL metabolism and has been found in other lipoproteins. Deficiency or mutation of apoE usually presents as an increase in apoB-containing lipoproteins such as VLDL and other chylomicrons. APOE has three major alleles (APOE2, APOE3 and APOE4) corresponding to the three major APOE isoforms (E2, E3 and E4). These are determined by variations in codons 130 and 176 giving six possible genotypes: 2/2, 2/3, 2/4, 3/3, 3/4 and 4/4. Although, APOE3/*3 (E3/E3) is the most common genotype and is considered as normal genotype this genotype is also associated with increase risk of atherosclerosis and cardiovascular disease. The genetic variation can directly impact the function of apoE, which then might result in deregulation of lipid metabolism such as in type III hyperlipoproteinemia.

Type III hyperlipoproteinemia (broad beta disease) is a familial dyslipidemia characterized by the combination of elevated serum cholesterol and triglycerides and the presence of the apolipoprotein E (apo E) genotype E2/E2. Type III hyperlipoproteinemia has an incidence of 1/2000 to 1/10,000. This lipid disorder is associated with a high risk of coronary heart disease and peripheral vascular disease. Onset of type III hyperlipoproteinemia is generally in adulthood but varies from late teens to old age. Before vascular disease develops there are usually no symptoms, and most patients with type III hyperlipoproteinemia are identified only from elevated serum cholesterol and triglycerides discovered during a routine screen. Symptoms include angina, heart attack, claudication, and leg pain. In untreated patients, xanthomas (fat deposits) are occasionally seen (flat in palmar creases or tuberous in joints).

The E2 variant of apolipoprotein E is defective in binding to receptors that normally clear harmful lipid particles called B-VLDL from the circulation. One percent of the general population has the E2/E2 genotype, and development of the frank lipid disorder occurs in 1% to 5% of these predisposed individuals, triggered by secondary genetic, hormonal, or environmental factors. Ninety-five percent of patients with type III hyperlipoproteinemia are homozygous for E2. Demonstration of the E2/E2 genotype is essential for diagnosis of type III hyperlipoproteinemia. However, most individuals (>90%) who are homozygous for the APOE2 allele will never develop this disease. Thus, the APOE genotype influences the development or clinical manifestation of type III hyperlipidemia, but is not the sole contributor. While there are rare case reports of APOE2 heterozygotes who develop type III hyperlipoproteinemia, APOE*2 heterozygotes are not generally considered to be predisposed to this disease.

Genotype e4 has been associated with increased risk of late onset Alzheimer’s disease. People who inherit one copy of the APOE e4 allele have an increased chance of developing the disease; those who inherit two copies of the allele are at even greater risk. Although, people with the APOE e4 allele have increased risk of developing Alzheimer disease, not all people with Alzheimer disease have the APOE e4 allele, and not all people who have this allele will develop the disease. In addition, APOE e4 is associated with increased risk for hypercholesterolemia and atherosclerosis, faster HIV disease progression, and accelerated telomere shortening.

  • As an aid in diagnosis of Type III hyperlipoproteinemia
  • Evaluate abnormal lipid metabolism associated with cardiovascular disease
  • Evaluate predisposing factor for the development of Alzheimer's disease in a patient with dementia
  • Differential diagnosis of Alzheimer’s disease
  • e3/e3: Most common (normal) genotype
  • e2/e2: Strongly association with hyperlipoproteinemia III
  • e4/e4: Associated with increased plasma cholesterol levels that may contribute to coronary heart disease
  • e4/e4: Associated with Alzheimer's disease but not diagnostic
  • e2/e3 or e2/e4: Some association with hyperlipoproteinemia III in patients heterozygous for familial hypercholesterolemia but not diagnostic
  • e3/e4: Some association with increased plasma cholesterol levels that may contribute to CHD but not diagnostic

e3/e3

Targeted mutation analysis by polymerase chain reaction (PCR), Phenotyping by Isoelectric Focusing (IEF).

Whole Blood EDTA (Lavender)

Stability

  • Ambient:  24 hours
  • Refrigerated: 72 hours
  • Frozen: Unacceptable
HDL Cholesterol, LDL Cholesterol, Lipid Profile, Triglycerides, Apolipoprotein B-100, High Sensitive CRP, Lipoprotein electrophoresis, Homocysteine, Apolipoprotein A-I, VLDL-C (very low density lipoprotein cholesterol), NMR Lipo profile, Liver panel.
Approximately 1 week.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login